Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Courtney D. DiNardo, MD, on Clinical Implications of Venetoclax and Azacitidine for Treatment-Naive Patients With AML

Posted: Tuesday, July 7, 2020

Courtney D. DiNardo, MD, of The University of Texas MD Anderson Cancer Center, discusses her findings on the benefits of venetoclax plus azacitidine vs azacitidine alone, concerns about tumor-lysis syndrome, and the need to delay treatment due to toxicity.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.